Results from the SURPASS-6 randomized clinical trial, comparing Tirzepatide to Insulin Lispro added to basal insulin in patients with Type 2 Diabetes, were published on 2023-01-01. This pivotal publication provides new data on treatment options for individuals whose diabetes is inadequately controlled.
Background
Tirzepatide, marketed as Mounjaro and Zepbound, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is approved for the treatment of Type 2 Diabetes and is also indicated for chronic weight management. Insulin Lispro (e.g., Humalog) is a rapid-acting insulin analog commonly used to control blood sugar levels, often in conjunction with basal insulin. The SURPASS program investigates Tirzepatide across various clinical settings for Type 2 Diabetes, aiming to provide comprehensive data on its efficacy and safety profile.
Trial design
The SURPASS-6 study was a randomized clinical trial designed to evaluate the efficacy and safety of Tirzepatide (LY3298176) compared to Insulin Lispro (U100). The trial specifically enrolled participants with Type 2 Diabetes whose condition was inadequately controlled on Insulin Glargine (U100), a basal insulin, either with or without concomitant metformin therapy. This design aimed to assess how Tirzepatide performs as an add-on therapy in a population already on basal insulin, providing a direct comparison to another established treatment for glycemic control.
What this means
The publication of the SURPASS-6 trial provides critical data for clinicians considering treatment intensification for patients with Type 2 Diabetes who are already on basal insulin and still experiencing inadequate glycemic control. The findings from this randomized clinical trial offer insights into the comparative effectiveness and safety profile of adding Tirzepatide versus Insulin Lispro in this specific patient population. This information is valuable for guiding treatment decisions and optimizing therapeutic strategies for managing Type 2 Diabetes, potentially impacting clinical practice for a significant patient demographic.
Source
The information regarding the SURPASS-6 randomized clinical trial was published in a journal article indexed by PubMed on 2023-01-01. The full details can be accessed via the PubMed database at pubmed.ncbi.nlm.nih.gov.